![Mark C. Enright](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark C. Enright
Corporate Officer/Principal chez Imperial College London
Profil
Mark C.
Enright is a Professor at Imperial College London since 2007.
He previously worked as a Research Director at AmpliPhi Biosciences Corp.
and Biocontrol Ltd.
(United Kingdom).
He obtained a doctorate degree from the University of Aberdeen.
Postes actifs de Mark C. Enright
Sociétés | Poste | Début |
---|---|---|
Imperial College London | Corporate Officer/Principal | 31/10/2011 |
Anciens postes connus de Mark C. Enright
Sociétés | Poste | Fin |
---|---|---|
Biocontrol Ltd. (United Kingdom)
![]() Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Mark C. Enright
University of Aberdeen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
AmpliPhi Biosciences Corp.
![]() AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Biocontrol Ltd. (United Kingdom)
![]() Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom. | Health Technology |